血液白细胞DNA甲基化预测未来心肌梗死与冠心病风险
基于美国与欧洲九个前瞻性人群队列,采用Illumina Infinium 450k芯片检测基线无冠心病个体的血液白细胞DNA甲基化,随访平均11.2年。
要点
- 血液白细胞DNA甲基化与未来冠心病风险相关,涉及52个CpG位点。
- 这些CpG位点映射至钙调节相关基因(如ATP2B2、CASR)及全基因组关联研究发现的基因。
- 孟德尔随机化支持DNA甲基化对冠心病发生的因果效应。
核心结论
- 血液来源DNA甲基化与多种人群未来冠心病风险相关,可能为深入了解冠心病发生提供信息工具。
研究设计与样本
- 九个来自美国和欧洲的人群队列,使用Illumina Infinium 450k芯片检测血液白细胞DNA甲基化,前瞻性确认冠心病事件。
- 各队列进行种族特异性分析,调整年龄、性别、吸烟、教育、体重指数、血细胞类型比例及技术变量,并采用固定效应荟萃分析。
主要发现
- 随访期间1895例发生冠心病。
- 52个CpG位点甲基化水平与冠心病或心肌梗死发生相关(错误发现率<0.05)。
- 这些CpG位点映射至钙调节关键基因(ATP2B2、CASR、GUCA1B、HPCAL1)及全基因组和表观基因组研究识别的基因(如CASR、PTPRN2、CDH23、HPCAL1)。
- 孟德尔随机化分析支持DNA甲基化对冠心病发生的因果效应,这些CpG位点映射至长链非编码RNA转录本附近的活性调控区域。
临床怎么用
- 血液DNA甲基化或可作为评估未来冠心病风险的潜在信息工具,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DNA methylation is implicated in coronary heart disease (CHD), but current evidence is based on small, cross-sectional studies. We examined blood DNA methylation in relation to incident CHD across multiple prospective cohorts. METHODS: Nine population-based cohorts from the United States and Europe profiled epigenome-wide blood leukocyte DNA methylation using the Illumina Infinium 450k microarray, and prospectively ascertained CHD events including coronary insufficiency/unstable angina, recognized myocardial infarction, coronary revascularization, and coronary death. Cohorts conducted race-specific analyses adjusted for age, sex, smoking, education, body mass index, blood cell type proportions, and technical variables. We conducted fixed-effect meta-analyses across cohorts. RESULTS: Among 11 461 individuals (mean age 64 years, 67% women, 35% African American) free of CHD at baseline, 1895 developed CHD during a mean follow-up of 11.2 years. Methylation levels at 52 CpG (cytosine-phosphate-guanine) sites were associated with incident CHD or myocardial infarction (false discovery rate<0.05). These CpGs map to genes with key roles in calcium regulation (ATP2B2, CASR, GUCA1B, HPCAL1), and genes identified in genome- and epigenome-wide studies of serum calcium (CASR), serum calcium-related risk of CHD (CASR), coronary artery calcified plaque (PTPRN2), and kidney function (CDH23, HPCAL1), among others. Mendelian randomization analyses supported a causal effect of DNA methylation on incident CHD; these CpGs map to active regulatory regions proximal to long non-coding RNA transcripts. CONCLUSION: Methylation of blood-derived DNA is associated with risk of future CHD across diverse populations and may serve as an informative tool for gaining further insight on the development of CHD.
引用
- Agha G, Mendelson MM, Ward-Caviness CK, et al. Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease. Circulation. 2019. PMID: 31424985. doi:10.1161/CIRCULATIONAHA.118.039357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。